Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevos principios activos para medicamentos útiles en el tratamiento de enfermedades inflamatorias, diabetes tipo 2, hipercolesterolemia, dislipidemias y aterosclerosis

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190311001
Publicado:
18/03/2019
Caducidad:
18/03/2020
Resumen:
Una universidad española ha desarrollado nuevos medicamentos para reducir los niveles de glucosa y colesterol con menos toxicidad que otros compuestos similares. Esta menor toxicidad podría implicar el desarrollo de un tratamiento más eficaz y tolerable para estas afecciones. Actualmente no existe en el mercado ningún compuesto derivado natural con estructura de benzopirano que regule estas alteraciones metabólicas. El principal sector de aplicación de estos compuestos (derivados de policerasoidol y policerasoidina) es el farmacéutico, ya que son principios activos de medicamentos para el tratamiento de la diabetes mellitus tipo 2, dislipidemias, síndrome metabólico y complicaciones asociadas, como enfermedades cardiovasculares e inflamatorias. La universidad busca socios con el fin de establecer acuerdos de licencia, cooperación técnica y/o financiación.

Details

Tittle:
New active principles for drugs useful in the treatment of inflammatory diseases, type 2 diabetes mellitus, hypercholesterolemia, dyslipidemias and atherosclerosis
Summary:
A Spanish university has developed new drugs which reduce glucose and cholesterol levels with less toxicity compared to other similar compounds. This lower toxicity could imply the development of a more effective and tolerable treatment for these conditions. There are no natural derivative compounds with benzopyran structure on the market that regulates these metabolic alterations. Researchers are looking for license or technical cooperation agreements and/or financial agreements with investors.
Description:
In the field of chemistry and pharmacology, different researchers have tried to develop treatments consisting of peroxisome proliferator-activated receptors agonists (PPARa and PPAR¿), involved in the regulation of lipids, carbohydrates and inflammation, making them therapeutic targets for the treatment of type 2 diabetes, metabolic syndrome, obesity, hyperlipidemias, cardiovascular diseases (atherosclerosis) and neurodegenerative diseases.
These compounds, in particular, the synthetic thiazolidinediones, have proved to be effective for treating some of these conditions, however, some of them failed due to their associated toxicity. Similarly, dual PPARa/PPAR¿ agonists such as saroglitazar are under surveillance. As a result, the treatment of the affected population is mainly carried out through a cocktail of different drugs such as statins, with their associated adverse effects, and hypoglycemic drugs.
This invention is the solution to toxicity problems of the others PPAR a/¿ agonists keeping treatment effectiveness. New compounds, Polycerasoidol and Polycerasoidin derivatives, have been developed to reduce glucose and cholesterol levels.
The main application sector of these compounds would be the pharmaceutical sector, as they can be active principles of drugs for the treatment of type 2 diabetes mellitus, dyslipidemias, metabolic syndrome and associated complications such as cardiovascular, inflammatory diseases. It is a great market due to the percentage of the population affected by these metabolic disorders has increased mainly due to new lifestyle habits (sedentary lifestyle and increased consumption of processed foods).
Researchers are seeking companies to reach license agreements. Technical cooperation with companies or research centers will be considered too, in order to make further progress in drug development. Finally, researchers are seeking investors interested in developing new drugs to carry out clinical trials through financial agreements.
Advantages and Innovations:
The most innovative aspect of this invention is that allows solving the toxicity problems of the others PPAR a/¿ agonists keeping the treatment effectiveness.
The main advantages provided by the invention are:
- Lower toxicity of these compounds compared to other PPAR agonists.
- Greater effectiveness against existing treatments such as cocktails of statins and hypoglycemic drugs
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent applied for in Spain

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Enterprise, research centers or investors.

- Specific area of activity of the partner: pharmaceutical activities, drug development, clinical trials.

- Task to be performed: licensing the invention, testing the drug, carrying out clinical trials, production and marketing of the product.

The Spanish university is looking for:
· Pharma companies to reach license agreements
· Pharma companies or research institutions to further co-development of the drug
· Pharma companies or investors to carry out clinical trials

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001002 Investigaciones clínicas, ensayos
06001015 Productos farmacéuticos / medicamentos
05001004 Química orgánica